Nadine Georges Rouphael MD

Infectious Disease•Atlanta, GA

Assistant Professor, Medicine, Emory University School of Medicine

Join to View Full Profile

550 Peachtree St NeAtlanta, GA 30308
Phone+1 404-686-1000

Education & Training

Emory University School of MedicineFellowship, Infectious Disease, 2005 - 2008
Emory University School of MedicineResidency, Internal Medicine, 2002 - 2005
St Joseph's University Medical SchoolClass of 2001

Certifications & Licensure

GA State Medical License 2005 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly Start of enrollment: 2010 Oct 01
Completed
Not Applicable
Systems Biology of PNEUMOVAX®23 and PREVNAR 13® Start of enrollment: 2014 Apr 01
Completed
Not Applicable
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly Start of enrollment: 2011 Jul 01
Completed
Not Applicable
Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics Start of enrollment: 2015 Apr 01
Completed
Not Applicable
Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Start of enrollment: 2017 Aug 29
ACTIVE_NOT_RECRUITING
PHASE2
Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD) Start of enrollment: 2019 Jan 11
Terminated
Phase 1, Phase 2
Responses to Rabies Vaccine in Adults With or Without Antibiotics Start of enrollment: 2018 Jul 05
Completed
Phase 4
Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) Start of enrollment: 2018 Nov 07
Terminated
Phase 4
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response Start of enrollment: 2018 Oct 11
Completed
Phase 4
Solid Organ Transplant SHINGRIX Start of enrollment: 2020 Jan 30
Terminated
Systems Biology of Zoster Vaccine Start of enrollment: 2019 Nov 14
COMPLETED
PHASE2
Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults Start of enrollment: 2020 Jan 13
COMPLETED
PHASE1
Immunophenotyping Assessment in a COVID-19 Cohort Start of enrollment: 2020 May 01
Completed
Influenza Human Challenge Model Start of enrollment: 2022 May 24
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Immunology of Ebola Vaccine Start of enrollment: 2024 Aug 06
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Durability of Vaccine Responses Start of enrollment: 2023 Apr 11
RECRUITING
PHASE4
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adju...
Theresa E Hegmann, Emmanuel B Walter, Michael J Smith, James Campbell, Hana M El Sahly
Vaccine. 2025-03-18
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant.
Mehul S Suthar, Kelly E Manning, Madison L Ellis, Shilpi Jain, Kareem Bechnak
The Lancet. Infectious Diseases. 2025-03-01
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
Hana M El Sahly, Evan J Anderson, Lisa A Jackson, Kathleen M Neuzil, Robert L Atmar
Vaccine. 2025-02-15

Journal Articles

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Nadine G Rouphael, Phillip A Swanson, Brett Leav, Varun K Phadke, The New England Journal of Medicine

Press Mentions

Blood Cells Linked to Long-Lasting Vaccine ImmunityJanuary 3rd, 2025
Blood Test Can Predict How Long Vaccine Immunity Will Last, Stanford Medicine-Led Study ShowsJanuary 2nd, 2025
More COVID-19 Cases but Fewer Working Treatments Against Shifting VirusDecember 16th, 2022
Join now to see all